Interactions between infections and immune-inflammatory cells in type 1 diabetes mellitus and inflammatory bowel diseases: Evidences from animal models

Clinical and Experimental Rheumatology

Volumn 26, Issue 1 SUPPL. 48, 2008, Pages

  Claesson, Mogens H ^a   Nicoletti, Ferdinando ^b   Stosic Grujicic, Stanislava ^c   Doria, Andrea ^d   Zampieri, Sandra ^d  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b UNIVERSITY OF CATANIA   (Italy)

^c UNIVERSITY OF BELGRADE   (Serbia)

^d UNIVERSITY OF PADOVA   (Italy)

Author keywords

Animal model; Inflammatory bowel disease; Macrophage migration inhibitory factor; Proinflammatory cytokines; Type 1 diabetes mellitus

Indexed keywords

CHEMOKINE RECEPTOR CXCR3; MACROPHAGE MIGRATION INHIBITION FACTOR; T LYMPHOCYTE RECEPTOR;

CD4+ CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CELL DESTRUCTION; COLITIS; CROHN DISEASE; CYTOKINE RELEASE; DENDRITIC CELL; DIABETOGENESIS; DISEASE ASSOCIATION; ENTERITIS; GENE EXPRESSION; IMMUNOREGULATION; INFECTION; INNATE IMMUNITY; INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; NONOBESE DIABETIC MOUSE; PANCREAS ISLET BETA CELL; PHENOTYPE; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; SCID MOUSE; TRANSGENIC MOUSE; ULCERATIVE COLITIS;

ANIMALS; DENDRITIC CELLS; DIABETES MELLITUS, TYPE 1; DISEASE MODELS, ANIMAL; INFECTION; INFLAMMATORY BOWEL DISEASES; T-LYMPHOCYTES, REGULATORY;

EID: 42549163788     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (36)

1. BACH JF: Insulin-dependent diabetes mellitus as an autoimmune disease. Endocr Rev 1994; 15: 516-42.
2. KAWADA M, ARIHIRO A, MIZOGUCHI E: Insights from advances in research of chemically induced experimental models of human inflammatory bowel disease. WJG 2007: 13: 5581-93.
3. TAPLIN CE, BARKER JM: Autoantibodies in type 1 diabetes. Autoimmunity. 2008; 41: 11-8.
4. BJØRNVOLD M, AMUNDSEN SS, STENE LC et al: FOXP3 polymorphisms in type 1 diabetes and coeliac disease. J Autoimmun 2006; 27: 140-4.
5. RAHBAR A, BOSTRÖM L, SÖDERBERG-NAUCLER C: Detection of cytotoxic CD13-specific autoantibodies in sera from patients with ulcerative colitis and Crohn's disease. J Autoimmun 2006; 26: 155-64.
6. SHOENFELD Y, MOLINA V: Infection, vaccines and other environmental triggers of autoimmunity. Autoimmunity 2005; 38: 235-45.
7. SARMIENTO L, CABRERA-RODE E, LEKULENI L et al.: Occurrence of enterovirus RNA in serum of children with newly diagnosed type 1 diabetes and islet cell autoantibody-positive subjects in a population with a low incidence of type 1 diabetes. Autoimmunity. 2007; 40: 540-5.
8. MÄKELÄ M, VAARALA O, HERMANN R, SALMINEN K et al.: Enteral virus infections in early childhood and an enhanced type 1 diabetes-associated antibody response to dietary insulin. J Autoimmun 2006; 27: 54-61.
9. FILIPPI C, VON HERRAT M: How viral infections affect the autoimmune process leading to type 1 diabetes. Cell Immunol 2005: 233: 125-32.
10. DIELEMAN LA, RIDWAN BU, TENNYSON GS, BEAGLEY KW, BUCY RP, ELSON CO: Dextran sulfate sodium-induced colitis odcurs in severe combined immunodeficient mice. Gastroenterology 1994; 107: 1643-54.
11. ANDERSSON A, HOLMDAHL R: A genetic basis for shared autoimmunity in mouse models. Autoimmunity 2005; 38: 209-17.
12. BAHARAV E, MOR F, HALPERN M, QUISTANA F, WEINBERGER A: Tropomyosin-induced arthritis in rats. Clin Exp Rheumatol 2007; 25 (Suppl. 45): S86-92.
13. YEUNG RS: Lessons learned from an animal model of Kawasaki disease. Clin Exp Rheamatol. 2007; 25 (Suppl. 44): S69-71.
14. VON HERRATH M, HOLTZ A: Pathological changes in the islet milieu precede infiltration of islet and destruction of beta-cells by autoreactive lymphocytes in a transgenic model of virus induced IDDM. J Autoimmun 1997; 10: 231-8.
15. TAKEI I, ASABA Y, KASATANI T et al.: Suppression of development of diabetes in NOD mice by lactate dehydrogenase virus infection. J Autoimmun 1992; 5: 665-73.
16. AOKI CA, BORCHERS AT, RIDGWAY WM, KEEN CL, ANSARI AA, GERSHWIN ME: NOD mice and autoimmunity. Autoimmun Rev 2005; 4: 323-410.
17. ALPEROVICH G, RAMA I, LLOBERAS N et al.: New immunosuppresor strategies in the treatment of murine lupus nephritis. Lupus 2007; 16: 18-24.
18. BRESSON D, VON HERRATH M: Moving towards efficient therapies in type 1 diabetes: To combine or not to combine? Autoimmun Rev 2007; 6: 315-22.
19. CVETKOVIC I, STOSIC-GRUJICIC S: Neutralization of macrophage migration inhibitory factor-novel approach for the treatment of immunoinflammatory disorders. Int Immunopharmacol 2006; 6: 1527-34.
20. WINTER WE, SCHATZ D: Prevention strategies for type 1 diabetes mellitus. Biodrugs 2003; 17: 39-64.
21. LIKE AA, ROSSINI A: Streptozotocin-induced pancreatic insulitis, a new model of diabetes mellitus. Science 1976; 193: 415-7.
22. ROEP BO, ATKINSON M, VON HERRATH M: Satisfaction (not) guaranteed: re-evaluating the use of animal models of type 1 diabetes. Nat Rev Immunol 2004; 4: 989-97.
23. RABINOVITCH A, SUAREZ-PINZON WL: Role of cytokines in the pathogenesis of autoimmune diabetes mellitus. Rev Endocr Metab Disord 2003; 4: 291-9.
24. CALANDRA T, ROGER T: Macrophage miAration inhibitory factor: a regulator of innate immunity. Nat Rev Immunol 2003; 3: 791-800.
25. LUE H, KLEEMANN R, CALANDRA T, ROGER T, BERNHAGEN J: Macrophage migration inhibitory factor (MEF): Mechanisms of action and role in disease. Microb Infect 2002; 4: 449-60.
26. CVETKOVIC I, AL-ABED Y, MILJKOVIC D et al.: Critical role of macrophage migration inhibitory factor activity in experimental autoimmune diabetes. Endocrinology 2005; 146: 2942-51.
27. STOSIC-GRUJICIC S, STOJANOVIC I, MAKSIMOVIC-IVANIC D et al.: Macrophage migration inhibitory factor (MIF) is necessary for progression of autoimmune diabetes mellitus. J Cell Physiol 2007 Dec 6; [Epub ahead of print].
28. AL-ABED Y, DABIDEEN D, ALJABARI B et al.: ISO-1 binding to the tautomerase active site of MIF inhibits its pro-inflammatory activity and increases survival in severe sepsis. J Biol Chem 2005; 4; 280: 36541-4.
29. KUMAR P, CLARK M: Clinical Medicine, 6th edition, Elsevier Saunders 2005.
30. POWRIE F, UHLIG H: Animal models of Cntestinal inflammation: clues to the pathogenesis of infl ammatory bowel disease. Novartis Found Symp 2004; 263: 164-74; discussion 174-8, 211-8.
31. + T lymphocytes injected into severe combined immunodeficient (SCID) mice lead to an inflammatory and lethal bowel disease. Clin Exp Immunol 1996; 104: 491-500.
32. SATOR RB: The influence of normal microbial flora on the development of chronic mucosal inflammation. Res Immunol 1997; 148: 567-76.
33. GAD M, KRISTENSEN N N, KURY E, CLAESSON MH: Characterization of T-regulatory cells, induced by immature dendritic cells, which inhibit enteroantigen-reactive colitis-inducing T-cell responses in vitro and in vivo. Immunology 2004; 113: 499-508.
34. KRISTENSEN NN, OLSEN J, GAD M, CLAESSON MH: Genome-wide expression profiling during protection from colitis by regulatory T cells. Inflamm Bowel Dis 2008; 14: 75-87.
35. + regulatory T cells. Inflamm Bowel Dis 2006; 12: 612-28.
36. - T cells in adoptive transfer colitis. Inflamm Bowel Dis 2006; 12: 374-81.